|
|
||||||||
,
,
*
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, OR 97213;
Department of Neuroimmunology, Veterans Affairs Medical Center, Portland, OR 97201; and
Department of Neurology, Oregon Health Sciences University, Portland, OR 97201
The OX-40R is a member of the TNF receptor family and is expressed primarily on activated CD4+ T cells. When the OX-40R is engaged by the OX-40 ligand (OX-40L), a potent costimulatory signal occurs. We have identified a population of CD11b+ cells, isolated from the central nervous system (CNS) of mice with actively induced experimental allergic encephalomyelitis (EAE), that expresses OX-40L. Moreover, the expression of OX-40L was found to be associated with paralytic episodes of EAE and was reduced or absent at disease recovery. These CD11b+ cells also coexpressed B7 and MHC class II. Therefore, to address the relative contributions of OX-40R/OX-40L and CD28/B7 to the costimulation of myelin-specific T cells, blocking studies were performed using soluble OX-40R and/or soluble CTLA-4. CD11b+ cells isolated from the CNS of mice with actively induced EAE were able to present Ag to proteolipid protein 139151-specific T cell lines in vitro. The addition of soluble OX-40R:Ig to CD11b+ brain microglia/macrophages inhibited T cell proliferation by 5070%. The addition of CTLA-4:Ig inhibited T cell proliferation by 2030%, and the combination inhibited T cell proliferation by 95%. In vivo administration of soluble OX-40R at the onset of actively induced or adoptively transferred EAE reduced ongoing signs of disease, and the mice recovered more quickly from acute disease. The data imply that OX-40L, expressed by CNS-derived APC, acts to provide an important costimulatory signal to EAE effector T cells found within the inflammatory lesions. Furthermore, the data suggest that agents designed to inhibit the OX-40L/OX-40R complex may be useful for treating autoimmune disease.
This article has been cited by other articles:
![]() |
C. E. Ruby, M. A. Yates, D. Hirschhorn-Cymerman, P. Chlebeck, J. D. Wolchok, A. N. Houghton, H. Offner, and A. D. Weinberg Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right J. Immunol., October 15, 2009; 183(8): 4853 - 4857. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Piconese, G. Gri, C. Tripodo, S. Musio, A. Gorzanelli, B. Frossi, R. Pedotti, C. E. Pucillo, and M. P. Colombo Mast cells counteract regulatory T-cell suppression through interleukin-6 and OX40/OX40L axis toward Th17-cell differentiation Blood, September 24, 2009; 114(13): 2639 - 2648. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Krause, M. Bruckner, C. Uermosi, E. Singer, M. Groettrup, and D. F. Legler Prostaglandin E2 enhances T-cell proliferation by inducing the costimulatory molecules OX40L, CD70, and 4-1BBL on dendritic cells Blood, March 12, 2009; 113(11): 2451 - 2460. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Gough, C. E. Ruby, W. L. Redmond, B. Dhungel, A. Brown, and A. D. Weinberg OX40 Agonist Therapy Enhances CD8 Infiltration and Decreases Immune Suppression in the Tumor Cancer Res., July 1, 2008; 68(13): 5206 - 5215. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. L. Redmond, M. J. Gough, B. Charbonneau, T. L. Ratliff, and A. D. Weinberg Defects in the Acquisition of CD8 T Cell Effector Function after Priming with Tumor or Soluble Antigen Can Be Overcome by the Addition of an OX40 Agonist J. Immunol., December 1, 2007; 179(11): 7244 - 7253. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Jenkins, G. Perona-Wright, A. G. F. Worsley, N. Ishii, and A. S. MacDonald Dendritic Cell Expression of OX40 Ligand Acts as a Costimulatory, Not Polarizing, Signal for Optimal Th2 Priming and Memory Induction In Vivo J. Immunol., September 15, 2007; 179(6): 3515 - 3523. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. J. Lepisto, M. Xu, H. Yagita, A. D. Weinberg, and R. L. Hendricks Expression and function of the OX40/OX40L costimulatory pair during herpes stromal keratitis J. Leukoc. Biol., March 1, 2007; 81(3): 766 - 774. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. J.A van Wanrooij, G. H.M van Puijvelde, P. de Vos, H. Yagita, T. J.C. van Berkel, and J. Kuiper Interruption of the Tnfrsf4/Tnfsf4 (OX40/OX40L) Pathway Attenuates Atherogenesis in Low-Density Lipoprotein Receptor-Deficient Mice Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 204 - 210. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. R. Maxwell, R. Yadav, R. J. Rossi, C. E. Ruby, A. D. Weinberg, H. L. Aguila, and A. T. Vella IL-18 Bridges Innate and Adaptive Immunity through IFN-{gamma} and the CD134 Pathway J. Immunol., July 1, 2006; 177(1): 234 - 245. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Soroosh, S. Ine, K. Sugamura, and N. Ishii OX40-OX40 Ligand Interaction through T Cell-T Cell Contact Contributes to CD4 T Cell Longevity J. Immunol., May 15, 2006; 176(10): 5975 - 5987. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Salek-Ardakani, T. So, B. S. Halteman, A. Altman, and M. Croft Protein Kinase C{theta} Controls Th1 Cells in Experimental Autoimmune Encephalomyelitis J. Immunol., December 1, 2005; 175(11): 7635 - 7641. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Y. Ma, S. A. Mikolajczak, A. Danesh, K. A. Hosiawa, C. M. Cameron, A. Takaori-Kondo, T. Uchiyama, D. J. Kelvin, and A. Ochi The expression and the regulatory role of OX40 and 4-1BB heterodimer in activated human T cells Blood, September 15, 2005; 106(6): 2002 - 2010. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. S. Schmidt, J. Zhao, J. Chain, D. Hepburn, B. Gitter, G. Sandusky, S. Chintalacharuvu, A. Glasebrook, and S. Na Resistance to Myelin Oligodendrocyte Glycoprotein-Induced Experimental Autoimmune Encephalomyelitis by Death Receptor 6-Deficient Mice J. Immunol., August 15, 2005; 175(4): 2286 - 2292. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Valzasina, C. Guiducci, H. Dislich, N. Killeen, A. D. Weinberg, and M. P. Colombo Triggering of OX40 (CD134) on CD4+CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR Blood, April 1, 2005; 105(7): 2845 - 2851. [Abstract] [Full Text] [PDF] |
||||
![]() |
M.-Y. Kim, V. Bekiaris, F. M. McConnell, F. M. C. Gaspal, C. Raykundalia, and P. J. L. Lane OX40 Signals during Priming on Dendritic Cells Inhibit CD4 T Cell Proliferation: IL-4 Switches off OX40 Signals Enabling Rapid Proliferation of Th2 Effectors J. Immunol., February 1, 2005; 174(3): 1433 - 1437. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Florido, M. Borges, H. Yagita, and R. Appelberg Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium J. Leukoc. Biol., November 1, 2004; 76(5): 1039 - 1046. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Weinberg, D. E. Evans, C. Thalhofer, T. Shi, and R. A. Prell The generation of T cell memory: a review describing the molecular and cellular events following OX40 (CD134) engagement J. Leukoc. Biol., June 1, 2004; 75(6): 962 - 972. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Andarini, T. Kikuchi, M. Nukiwa, P. Pradono, T. Suzuki, S. Ohkouchi, A. Inoue, M. Maemondo, N. Ishii, Y. Saijo, et al. Adenovirus Vector-Mediated in Vivo Gene Transfer of OX40 Ligand to Tumor Cells Enhances Antitumor Immunity of Tumor-Bearing Hosts Cancer Res., May 1, 2004; 64(9): 3281 - 3287. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Takeda, S. Ine, N. Killeen, L. C. Ndhlovu, K. Murata, S. Satomi, K. Sugamura, and N. Ishii Distinct Roles for the OX40-OX40 Ligand Interaction in Regulatory and Nonregulatory T Cells J. Immunol., March 15, 2004; 172(6): 3580 - 3589. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Toennies, J. M. Green, and R. H. Arch Expression of CD30 and Ox40 on T lymphocyte subsets is controlled by distinct regulatory mechanisms J. Leukoc. Biol., February 1, 2004; 75(2): 350 - 357. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Martin-Orozco, Z. Chen, L. Poirot, E. Hyatt, A. Chen, O. Kanagawa, A. Sharpe, D. Mathis, and C. Benoist Paradoxical Dampening of Anti-Islet Self-Reactivity but Promotion of Diabetes by OX40 Ligand J. Immunol., December 15, 2003; 171(12): 6954 - 6960. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. R. Humphreys, G. Walzl, L. Edwards, A. Rae, S. Hill, and T. Hussell A Critical Role for OX40 in T Cell-mediated Immunopathology during Lung Viral Infection J. Exp. Med., October 20, 2003; 198(8): 1237 - 1242. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Wilson, C. P. Rossi, S. Carboni, C. Fremaux, D. Perrin, C. Soto, M. Kosco-Vilbois, and A. Scheer A Homogeneous 384-Well High-Throughput Binding Assay for a TNF Receptor Using Alphascreen Technology J Biomol Screen, October 1, 2003; 8(5): 522 - 532. [Abstract] [PDF] |
||||
![]() |
S. Salek-Ardakani, J. Song, B. S. Halteman, A. G.-H. Jember, H. Akiba, H. Yagita, and M. Croft OX40 (CD134) Controls Memory T Helper 2 Cells that Drive Lung Inflammation J. Exp. Med., July 21, 2003; 198(2): 315 - 324. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. R. Blazar, A. H. Sharpe, A. I. Chen, A. Panoskaltsis-Mortari, C. Lees, H. Akiba, H. Yagita, N. Killeen, and P. A. Taylor Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients Blood, May 1, 2003; 101(9): 3741 - 3748. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Yuan, A. D. Salama, V. Dong, I. Schmitt, N. Najafian, A. Chandraker, H. Akiba, H. Yagita, and M. H. Sayegh The Role of the CD134-CD134 Ligand Costimulatory Pathway in Alloimmune Responses In Vivo J. Immunol., March 15, 2003; 170(6): 2949 - 2955. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Gri, E. Gallo, E. Di Carlo, P. Musiani, and M. P. Colombo OX40 Ligand-Transduced Tumor Cell Vaccine Synergizes with GM-CSF and Requires CD40-Apc Signaling to Boost the Host T Cell Antitumor Response J. Immunol., January 1, 2003; 170(1): 99 - 106. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Ekkens, Z. Liu, Q. Liu, J. Whitmire, S. Xiao, A. Foster, J. Pesce, J. VanNoy, A. H. Sharpe, J. F. Urban, et al. The Role of OX40 Ligand Interactions in the Development of the Th2 Response to the Gastrointestinal Nematode Parasite Heligmosomoides polygyrus J. Immunol., January 1, 2003; 170(1): 384 - 393. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Murata, M. Nose, L. C. Ndhlovu, T. Sato, K. Sugamura, and N. Ishii Constitutive OX40/OX40 Ligand Interaction Induces Autoimmune-Like Diseases J. Immunol., October 15, 2002; 169(8): 4628 - 4636. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Taylor, M. Bachler, I. Duncan, S. Keen, R. Fallon, C. Mair, T. T. McDonald, and H. Schwarz In vitro and in vivo activities of OX40 (CD134)-IgG fusion protein isoforms with different levels of immune-effector functions J. Leukoc. Biol., September 1, 2002; 72(3): 522 - 529. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. W. Chan, C. D. Hopke, S. M. Krams, and O. M. Martinez CD30 Expression Identifies the Predominant Proliferating T Lymphocyte Population in Human Alloimmune Responses J. Immunol., August 15, 2002; 169(4): 1784 - 1791. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Yamada, A. D. Salama, and M. H. Sayegh The Role of Novel T Cell Costimulatory Pathways in Autoimmunity and Transplantation J. Am. Soc. Nephrol., February 1, 2002; 13(2): 559 - 575. [Full Text] [PDF] |
||||
![]() |
T. De Smedt, J. Smith, P. Baum, W. Fanslow, E. Butz, and C. Maliszewski Ox40 Costimulation Enhances the Development of T Cell Responses Induced by Dendritic Cells In Vivo J. Immunol., January 15, 2002; 168(2): 661 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Evans, R. A. Prell, C. J. Thalhofer, A. A. Hurwitz, and A. D. Weinberg Engagement of OX40 Enhances Antigen-Specific CD4+ T Cell Mobilization/Memory Development and Humoral Immunity: Comparison of {alpha}OX-40 with {alpha}CTLA-4 J. Immunol., December 15, 2001; 167(12): 6804 - 6811. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. C. Ndhlovu, N. Ishii, K. Murata, T. Sato, and K. Sugamura Critical Involvement of OX40 Ligand Signals in the T Cell Priming Events During Experimental Autoimmune Encephalomyelitis J. Immunol., September 1, 2001; 167(5): 2991 - 2999. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Baba, Y. Takahashi, J. Lichtenfeld, R. Tanaka, A. Yoshida, K. Sugamura, N. Yamamoto, and Y. Tanaka Functional CD4 T Cells after Intercellular Molecular Transfer of OX40 Ligand J. Immunol., July 15, 2001; 167(2): 875 - 883. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Malmstrom, D. Shipton, B. Singh, A. Al-Shamkhani, M. J. Puklavec, A. N. Barclay, and F. Powrie CD134L Expression on Dendritic Cells in the Mesenteric Lymph Nodes Drives Colitis in T Cell-Restored SCID Mice J. Immunol., June 1, 2001; 166(11): 6972 - 6981. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Nohara, H. Akiba, A. Nakajima, A. Inoue, C.-S. Koh, H. Ohshima, H. Yagita, Y. Mizuno, and K. Okumura Amelioration of Experimental Autoimmune Encephalomyelitis with Anti-OX40 Ligand Monoclonal Antibody: A Critical Role for OX40 Ligand in Migration, But Not Development, of Pathogenic T Cells J. Immunol., February 1, 2001; 166(3): 2108 - 2115. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Cua, B. Hutchins, D. M. LaFace, S. A. Stohlman, and R. L. Coffman Central Nervous System Expression of IL-10 Inhibits Autoimmune Encephalomyelitis J. Immunol., January 1, 2001; 166(1): 602 - 608. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Kjærgaard, J. Tanaka, J. A. Kim, K. Rothchild, A. Weinberg, and S. Shu Therapeutic Efficacy of OX-40 Receptor Antibody Depends on Tumor Immunogenicity and Anatomic Site of Tumor Growth Cancer Res., October 1, 2000; 60(19): 5514 - 5521. [Abstract] [Full Text] |
||||
![]() |
I. Gramaglia, A. Jember, S. D. Pippig, A. D. Weinberg, N. Killeen, and M. Croft The OX40 Costimulatory Receptor Determines the Development of CD4 Memory by Regulating Primary Clonal Expansion J. Immunol., September 15, 2000; 165(6): 3043 - 3050. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Tsukada, H. Akiba, T. Kobata, Y. Aizawa, H. Yagita, and K. Okumura Blockade of CD134 (OX40)-CD134L interaction ameliorates lethal acute graft-versus-host disease in a murine model of allogeneic bone marrow transplantation Blood, April 1, 2000; 95(7): 2434 - 2439. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. D. Weinberg, M.-M. Rivera, R. Prell, A. Morris, T. Ramstad, J. T. Vetto, W. J. Urba, G. Alvord, C. Bunce, and J. Shields Engagement of the OX-40 Receptor In Vivo Enhances Antitumor Immunity J. Immunol., February 15, 2000; 164(4): 2160 - 2169. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Akiba, Y. Miyahira, M. Atsuta, K. Takeda, C. Nohara, T. Futagawa, H. Matsuda, T. Aoki, H. Yagita, and K. Okumura Critical Contribution of Ox40 Ligand to T Helper Cell Type 2 Differentiation in Experimental Leishmaniasis J. Exp. Med., January 17, 2000; 191(2): 375 - 380. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Murata, N. Ishii, H. Takano, S. Miura, L. C. Ndhlovu, M. Nose, T. Noda, and K. Sugamura Impairment of Antigen-Presenting Cell Function in Mice Lacking Expression of Ox40 Ligand J. Exp. Med., January 17, 2000; 191(2): 365 - 374. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Lane Role of Ox40 Signals in Coordinating Cd4 T Cell Selection, Migration, and Cytokine Differentiation in T Helper (Th)1 and Th2 Cells J. Exp. Med., January 17, 2000; 191(2): 201 - 206. [Full Text] [PDF] |
||||
![]() |
S. D. Pippig, C. Pena-Rossi, J. Long, W. R. Godfrey, D. J. Fowell, S. L. Reiner, M. L. Birkeland, R. M. Locksley, A. N. Barclay, and N. Killeen Robust B Cell Immunity but Impaired T Cell Proliferation in the Absence of CD134 (OX40) J. Immunol., December 15, 1999; 163(12): 6520 - 6529. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |